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Abstract
Background: Mitochondrial membrane complexes (MMCs) are key mediators of cellular oxidative phosphorylation,
and inhibiting them could lead to cell death. No published data are available on the relative abundance of MMCs
in different periampullary cancers. Therefore, we studied the expression profile of MMCs I, III, IV and V in
periampullary cancers, reactive pancreatitis, normal pancreas and chronic pancreatitis.
Methods: This was a retrospective study on tissue microarrays constructed from formalin-fixed paraffin-embedded
tissue from 126 consecutive patients (cancer = 104, chronic pancreatitis = 22) undergoing pancreatic resections
between June 2001 and June 2006. 78 specimens of chronic pancreatitis tissue were obtained adjacent to areas of
cancer. Normal pancreatic tissue was obtained from the resection specimens in a total of 30 patients. Metastatic
tumours in 61 regional lymph nodes from 61 patients were also studied.
Results: MMCs I, III, IV and V were highly expressed (p < 0.05) in all primary periampullary cancers compared with
metastatic lymph nodes and adjacent benign pancreas. MMCs III, IV and V were highly expressed in all cancers
regardless of type compared with chronic pancreatitis (p < 0.05). Higher expression of MMCs I and V was
associated with better survival and may, in part, relate to lower expression of these MMCs in poorly differentiated
tumours compared with well and moderately differentiated tumours.
Conclusions: Differential expression of MMCs III, IV and V in primary periampullary cancers compared with
adjacent benign periampullary tissue and chronic pancreatitis is a novel finding, which may render them attractive
anticancer targets.
Background
The mitochondrial respiratory chain complexes or mito-
chondrial membrane complexes (MMCs) I, II, III and
IV are proteins responsible for electron transport and
the associated proton pumping which generates a pro-
ton gradient and mitochondrial membrane potential
which is then used (via ATP synthase, complex V) to
generate adenosine-5’-triphosphate (ATP), the central
energy currency of the cell. Mitochondria also play a
key role in apoptosis, through the modulation of mem-
brane potential and the co-ordinated release of mito-
c h o n d r i a lp r o t e i n ss u c ha sc y t o c h r o m ec [1].
Mitochondrial complexes have also been shown to be
specific targets for drug therapy in cancer and drugs
called “mitocans” [2-5] can disrupt the integrity of mito-
chondria causing cytosolic release of modulators of
apoptosis and activation of mitochondria-dependent cell
death signalling pathways inside cancer cells [6-8].
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agents is interesting, their safety and efficacy are depen-
dent on their selectivity in targeting malignant tissue
over normal tissue in inducing apoptosis [7,9-11]. A key
approach to targeting mitochondrial components
involves blocking the electron transport chain by inhi-
biting MMCs I, II, III, IV and V [11,12]. What is key to
effecting some paradigms of mitochondrially-mediated
apoptosis is the ability to induce a sufficiently large
decrease in mitochondrial membrane potential, which
m a yb em a d ep o s s i b l eb yi n h i b i t i n ga n yo n es p e c i f i c
mitochondrial membrane.
Several classes of drugs are capable of achieving this
in vitro [12-15], but before these agents are investigated
clinically in specific cancers it is critical to ascertain the
relative expression of these target membrane complexes
in malignant tissue compared to benign tissue. Such a
mechanistic approach would enable selection of mito-
cans that are target specific with least toxicity and opti-
mal efficacy.
Periampullary cancer is a collective term used for can-
cers arising from or near the ampulla of Vater and
include ampullary cancers, duodenal cancers, pancreatic
head cancer and distal cholangiocarcinoma. As the rela-
tive expression of MMCs in malignant and benign pan-
creatic epithelium has not yet been characterized, we
performed this study to determine the immunohisto-
chemical expression of MMCs in tissue microarrays
(TMAs) of formalin-fixed archived specimens of periam-
pullary cancers (pancreatic ductal adenocarcinoma,
ampullary adenocarcinoma, cholangiocarcinoma and
duodenal adenocarcinoma), chronic pancreatitis, and
normal pancreatic tissue, and to determine any associa-
tion of MMC expression in cancer with survival.
Methods
Study design, setting and ethics
This immunohistochemical study was performed on
archived formalin-fixed pancreatic tissues from all
patients who underwent pancreatic resections between
June 2001 and June 2006 at Nottingham University Hos-
pitals, Queen’s Medical Centre, Nottingham, UK. The
Ethics Committee of Nottingham University Hospitals
approved the conduct of this study.
Subjects
We included 126 consecutive patients who underwent
pancreatic resections (104 for cancer and 22 for chronic
pancreatitis) [16]. Additional specimens of chronic pan-
creatitis tissue were obtained from areas of inflamma-
tion adjacent to cancers. Normal pancreatic tissue was
obtained from the resection specimens, adjacent to areas
of cancer or chronic pancreatitis. Metastatic lymph
nodes from patients with cancers were also studied.
Construction of tissue microarrays
Formalin-fixed, paraffin-embedded tissue blocks con-
taining pancreatic ductal adenocarcinoma, ampullary
adenocarcinoma, cholangiocarcinoma, duodenal adeno-
carcinoma, chronic pancreatitis and normal pancreatic
tissue were identified on haematoxylin and eosin stained
slides, marked by a single histopathologist (AMZ) and
tissue microarrays (TMAs) were constructed in triplicate
by a method previously used by us [16].
Immunohistochemical staining
Slides were deparaffinized in xylene, then hydrated via
graded dilutions of alcohol followed by running tap
water. Following a rinse in de-ionized water, the sec-
tions were pre-treated with boiling sodium citrate 10
mM pH 6.0 for 23 min to unmask antigenicity. Subse-
quently, a Labelled Streptavidin Biotin (LSAB) immu-
noperoxidase procedure was performed using 3,3’-
diaminobenzidine (DAB) as the chromogen on a Tech-
Mate 500+ automated stainer (Dako UK Ltd., Ely, UK).
The staining protocol consisted of incubating the sec-
tions with 0.3% hydrogen peroxide for 10 min to block
endogenous peroxidase, washing in phosphate buffered
saline (PBS) buffer, and incubation in goat serum for
20 min. After washing, the slides were incubated with
mouse anti-mitochondrial, OXPHOS complexes I, III,
IV and V antibodies (Invitrogen, Paisley, UK) at an
optimal dilution of 1:20, 1:20, 1:20 and 1:100, respec-
tively, in an antibody diluent (S2022; Dako) for 1 h at
room temperature, followed by further washing in PBS.
Sections were then incubated with a biotin linked sec-
ondary antibody for 30 min followed by washing in
PBS and then streptavidin-horseradish peroxidase (30
min) using a reagent kit from Dako (K5001). Immu-
nostaining was visualized using DAB present in the
above kit for 10 min, followed by light counterstaining
with haematoxylin. Negativec o n t r o l sw e r ea l s op e r -
formed on TMAs using diluent only. The control
TMAs did not stain positively, confirming the positive
staining observed using this protocol was that of
MMCs I, III, IV and V. Liver sections were used as
positive controls.
Immunohistochemical scoring
MMC expression was calculated by combining an esti-
mate of the percentage of immunoreactive cells (quan-
tity score) with an estimate of the staining intensity
(staining intensity score) as follows: no staining was
scored as 0, 1-10% of cells with positive staining were
scored as 1, 10-50% as 2, 50-70% as 3, and 70-100% as
4. Staining intensity was rated on a scale of 0 to 3 as fol-
lows: 0 = negative (no colour); 1 = weak brown, 2 =
moderate brown, and 3 = strong brown. The raw data
were converted to the immunohistochemical score (IHS)
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Therefore, the score could range from 0 to 12. An IHS
≥ 2 was considered as positive expression [17]. Staining
was further categorized as high (score >8) or low (score
≤ 8), based on the median staining score of 8 for all
MMCs. Immunohistochemical scoring was performed
independently by two observers (MMA and AMZ) and
the inter-observer variability was <3%.
Proliferative capacity
Proliferative capacity of the cancers was evaluated using
a well established method and represented as the
volume corrected mitotic index (VCMI) [18]. This was
also performed by 2 independent observers (MMA and
AMZ) and the inter-observer variability was <3%.
Statistics
Statistical analysis was performed using SPSS v16.0 for
Mac (SPSS Inc., Chicago, IL, USA). Means were com-
pared using the Student t-test. One way ANOVA was
used when comparing 3 or more groups. Results were
considered significant at p < 0.05. Correlations were
performed using Pearson’s correlation test. Survival ana-
lysis was carried out using the Kaplan-Meier method
with log rank Mantel Cox comparison.
Results
Of the 126 consecutive patients who underwent pan-
creatic resections 104 (62 male) with a median (IQR)
age of 64 (59-72) years had cancer and 22 (15 male)
with a median (IQR) age of 55 (41-61) years had chronic
pancreatitis. Specimens of chronic pancreatitis tissue
were obtained from areas adjacent to cancer in 78
patients. Normal pancreatic tissue was obtained from
the resection specimens, adjacent to areas of cancer or
chronic pancreatitis in a totalo f3 0p a t i e n t s .S i x t y - o n e
metastatic lymph nodes from 61 patients were also stu-
died [16]. Of the 104 patients with cancer, 31 (15 male)
had ampullary adenocarcinoma, 24 (15 male) had cho-
langiocarcinoma, 44 (29 male) had pancreatic ductal
adenocarcinoma and 5 (3 male) had duodenal adenocar-
cinoma. The ratios of well:moderately:poorly differen-
tiated tumours were 7:16:8, 1:18:5, 5:28:11 and 0:5:0 for
ampullary adenocarcinoma, cholangiocarcinoma, pan-
creatic ductal adenocarcinoma and duodenal adenocar-
cinoma respectively. Vascular invasion was present in 13
(42%), 8 (33%), 22 (50%) and 1 (20%) patients with
ampullary adenocarcinoma, cholangiocarcinoma, pan-
creatic ductal adenocarcinoma and duodenal adenocar-
cinoma respectively. Corresponding figures for
perineural invasion were 12 (39%), 14 (58%), 30 (68%)
and 2 (40%) and those for lymphatic invasion were 12
(39%), 14 (58%), 26 (59%) and 4 (80%). Tumours were ≥
2 cm in diameter in 12 (39%), 7 (29%), 15 (34%) and 2
(40%) patients with ampullary adenocarcinoma, cholan-
giocarcinoma, pancreatic ductal adenocarcinoma and
duodenal adenocarcinoma respectively. AICC disease
stage distribution (Ia:Ib:II) was 12 (39%):11 (35%):8
(26%) for those with ampullary adenocarcinoma, 7
(29%):7 (29%):10 (42%) for cholangiocarcinoma, 15
(34%):12 (27%):17 (39%) for pancreatic ductal adenocar-
cinoma and 2 (40%):2 (40%):1 (20%) for duodenal
adenocarcinoma.
MMC by grade of the tumour
The immunohistochemical scores for MMCs I, III, IV
and V, categorized as high or low expressors by
tumour grade for various periampullary tumour types,
are summarized in Table 1. Across tumour grades the
ratios of high to low expressors of MMCs I, III and IV
were comparable. However, for MMC V the ratios
were reversed for poorly differentiated tumours com-
pared to well or moderately differentiated tumours, i.e.
poorly differentiated tumours tended to show low
expression of MMC V, compared to well and moder-
ately differentiated tumours (Table 1). Moreover, high
MMC V expression showed a statistically significant
inverse correlation with the number of lymph node
metastases (Pearson’s correlation coefficient of -0.314,
2 tailed significance of p < 0.001). Volume corrected
mitotic index (VCMI) showed an inverse correlation
with enhanced MMC I expression (Pearson’sc o r r e l a -
tion coefficient of -0.231, 2 tailed significance of
p < 0.001).
MMC expression by tissue type in the same tumour and
by diagnosis
MMC I expression in cancer was not significantly higher
than in benign tissue. A significantly greater expression
of MMCs III, IV and V was noted in cancer cells com-
pared with surrounding benign tissue (reactive pancrea-
titis or normal pancreas) (Figures 1, 2, 3 and 4). The
pattern of expression is summarized in Figure 5. In con-
trast to differential expression within tissues of the same
tumour, MMC expression across a range of periampul-
lary cancer types showed an increased expression in all
of them compared with chronic pancreatitis MMCs III,
IV and V (Figure 6).
There was a tendency to better survival in patients
who showed high expression of MMC I in their cancer
compared with those who had no or low expression of
MMC I, although this did not reach statistical signifi-
cance (Kaplan Meier, Mantel Cox p = 0.08). However,
higher expression of MMC V in the cancer, was asso-
ciated with better survival (Kaplan Meier, Mantel Cox
p = 0.005). This may, in part, relate to lower expres-
sion of these MMCs in poorly differentiated tumours
compared to well and moderately differentiated
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Page 3 of 11Figure 1 Expression of MMC I. (a and b) Normal pancreatic acini showing weak expression; (c) Chronic pancreatitis tissue showing weak acinar
expression but no expression in the pancreatic duct (arrow); (d and e) Pancreatic cancer showing strong expression; (f) Metastatic cancer in
lymph node showing strong expression (Magnification for all images ×40)
Table 1 Distribution by immunoscore of mitochondrial membrane complexes (MMC) I, III, IV and V among all
periampullary cancers.
MMC Immunoscore Statistic Degree of differentiation
(Range 0-12) Well Moderate Poor
I High expressors No. of patients 5 25 5
(Score >8) Mean (SD) immunoscore 12 (0) 12 (0) 12 (0)
Low expressors No. of patients 8 42 19
(Score ≤ 8) Mean (SD) immunoscore 7 (2) 7 (2) 8 (1)
III High expressors No. of patients 6 40 14
(Score >8) Mean (SD) immunoscore 12 (0) 12 (0) 12 (0)
Low expressors No. of patients 7 27 10
(Score ≤ 8) Mean (SD) immunoscore 7 (2) 7 (2) 8 (0)
IV High expressors Count (no. of patients) 6 33 14
(Score >8) Mean (SD) immunoscore 12 (0) 12 (0) 12 (0)
Low expressors Count (no. of patients) 7 34 10
(Score ≤ 8) Mean (SD) immunoscore 7 (2) 7 (2) 7 (1)
V High expressors Count (no. of patients) 8 35 7
(Score >8) Mean (SD) immunoscore 11 (2) 10 (2) 9 (2)
Low expressors Count (no. of patients) 5 32 17
(Score ≤ 8) Mean (SD) immunoscore 2 (2) 2 (2) 2 (1)
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sion of MMC V showed inverse correlation with
lymph node metastases (r = -0.314, p < 0.001) and
high VCMI (r = -0.231, p = 0.018).
Discussion
This study has shown that MMCs I, III, IV and V are
highly expressed in periampullary cancers compared
with metastatic cancer in lymph nodes or benign peri-
ampullary tissue for MMCs III, IV and V. MMC II
expression was not studied because of non-availability
of a suitable monoclonal antibody for immunostaining
of formalin-fixed tissues. Normal ductal cells exhibit
very low levels of staining, which may be to due to low
levels of mitochondrial expression in these cells, and/
or the limited sensitivity of the methods/antibodies
used. This, to the best of our knowledge, is the first
study demonstrating a differential expression of MMCs
in malignant compared with benign periampullary tis-
sue. In future studies, we will also correlate our data
with the expression of the tricarboxylic acid (TCA)
cycle (Krebs’ cycle) enzyme citrate synthase which has
Figure 2 Expression of MMC III. (a) Strong expression in pancreatic cancer (×60); with weak expression in adjacent benign pancreatic duct
epithelium (arrow); (b) Strong expression in pancreatic cancer (×40); (c) Chronic pancreatitis (×60) showing weak expression in the acini but no
expression in the ductal epithelium (arrow); (d) Normal pancreas (×40) showing very weak expression.
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allow detection of mitochondria in ductal cells due to
its high level of expression in normal cells. Cancer
cells are capable of withstanding an adverse microen-
vironment (hypoxia, acidosis, hypoglycaemia, and
shortage of growth factors) by virtue of metabolic
adaptation [19]. MMCs I and III, in addition to their
role as proton carriers in the electron transport chain,
are known to be crucial mediators for hypoxia induced
reactive oxygen production [20-22]. Such a mechanism
is crucial for cellular survival in adverse hypoxic condi-
tions. Therefore, a differentially higher expression of
MMCs in primary periampullary cancer, compared
with metastatic lymph nodes or benign periampullary
tissue may represent an adaptive mechanism to
chronic cellular hypoxia.
Periampullary cancers carry a poor prognosis due to
their insensitivity to most conventional therapies
[23,24]. Currently, surgical resection offers the only
potential chance for a cure in these patients. The 5-year
Figure 3 Expression of MMC IV. (a and b) Weak expression in benign pancreatic acini (×40); with no expression in the ductal epithelium
(arrows); (c and d) Strong expression in pancreatic cancer (×40).
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below 5%, and the median survival time after diagnosis
is 6 months and only about 20% of patients who
undergo curative resection survive longer than 5 years
[25].
One mechanism of action of mitochondrial targeted
anti-cancer drugs relies on their ability to disrupt the
energy producing systems of cancer cell mitochondria,
leading to increased reactive oxygen species and activa-
tion of the mitochondrial dependent cell death signal-
ing pathways inside cancer cells. This emerging class
of drugs called “mitocans” should act by altering prop-
erties of the mitochondria inside cancerous but not
normal cells for instance by reducing the resting mem-
brane potential by blocking the electron transport
chain. It is clear from the present studies that mito-
cans offer great potential as effective and exciting new
developments in cancer therapy, providing direct
activation of cancer cell death by mitochondrial
mediated apoptosis and that this complements the
other pathways by which existing treatments kill can-
cer cells [2-5]. A proof of concept for MMC targeted
therapy is the ability of clomipramine induced inhibi-
tion of MMC-III in cancer cells, as previous shown by
our group [12]. Vitamin E analogues [4] have been
shown to be an inhibitor of MMC II and tamoxifen,
an inhibitor of MMC I [26].
Mitochondria-mediated anti-cancer therapy may also
rely on manipulation of tumour suppressor proteins that
are encoded by mitochondrial membrane complex
genes. These genes include the succinate dehydrogenase
(SDH) encoder. SDH is part of the TCA cycle that con-
nects glucose metabolism in the cytosol to oxidative
phosphorylation in the mitochondria and is the only
membrane-bound enzyme of the TCA cycle and is also
a functional member (complex II) of the electron
Figure 4 Expression of MMC V. (a) Lack of expression in a benign pancreatic ductal epithelium (×80); (b-d) strong expression in pancreatic
cancer (×80); (b and c) well differentiated adenocarcinoma (×80); (d) poorly differentiated adenocarcinoma (×80).
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have been shown to lead to the development of phaeo-
chromocytomas and paraganglionomas [27].
However, the clinical safety and efficacy of potential
anti-mitochondrial therapies in periampullary tumours
lies in the selective targeting of malignant epithelium
with relative sparing of benign tissue. The prudent
choice of a MMC targeting agent would depend on its
differential expression between malignant and benign
tissue.
Enhanced expression of MMCs III and V in tumours
compared with chronic pancreatitis supports their
mechanistic safety when administered to diagnostically
uncertain pancreatic cancers, which may turn out to be
chronic pancreatitis. Moreover, high expression of some
of these MMCs (I and V) may be associated with better
survival, by suppressing tumour biological factors like
proliferative capacity and lymph node metastasis.
Conclusions
MMC III, IV and V targeting in periampullary cancers is
mechanistically viable based on their characteristic
expression profiles, indicating that such targeting strate-
gies can be selective and therefore likely to be effective
with minimal collateral damage to benign pancreatic
tissue.
Figure 5 Expression of MMCs observed in various tissues within resection specimens. (a) Mean (SE) immunoscore across various tissue
types in the same tumour specimen for MMC I; (b) Mean (SE) immunoscore across various tissue types in the same tumour specimen for MMC
III; (c) Mean (SE) immunoscore across various tissue types in the same tumour specimen for MMC IV; (d) Mean (SE) immunoscore across various
tissue types in the same tumour specimen for MMC V. All comparisons were made with the primary tumour (*p < 0.001, # not significant).
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Page 8 of 11Figure 6 Expression of MMCs across tumour types. (a) Mean (SE) immunoscore across different diagnoses for MMC III, cancers, chronic
pancreatitis; (b) Mean (SE) immunoscore across different diagnoses for MMC IV; cancers (5.4-7.0, 95% CI), chronic pancreatitis; (c) Mean (SE)
immunoscore across different diagnoses for MMC V; cancers, chronic pancreatitis. Comparisons of each tumour type made with chronic
pancreatitis were significant at p < 0.001).
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Page 9 of 11Figure 7 Survival. (a) Disease specific survival of high versus low expressors of MMC I. A trend for better survival was observed in high
expressors compared with low expressors (p = 0.08); (b) Disease specific survival of high versus low expressors of MMC V. High expressors
survived significantly longer than low expressors (p = 0.005).
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